ARTICLE | Clinical News

Alinia nitazoxanide: Pilot trial data

November 15, 2010 8:00 AM UTC

An open-label pilot trial in 5 liver transplant patients showed that oral Alinia reduced HCV viral load in all patients during the first 72 hours post-transplant. However, HCV RNA levels were similar to pre-transplant levels within 4 days after completing therapy and no patients remained HCV-RNA-negative after liver transplantation. Alinia was well tolerated, with abdominal pain and nausea reported as the primary adverse events. Patients received twice-daily 1,000 mg Alinia immediately prior to transplant and for 72 hours post-transplant. Data were presented at the American Association for the Study of Liver Diseases meeting in Boston. ...